Meet the newest additions to the MATTER community

Our newest MATTER members are challenging conventional views of cancer treatment, helping reduce the effects of dry eye in North America and revolutionizing personal care monitoring.

Tieös Pharmaceuticals

Tieös Pharmaceuticals was formed in an operating room theater by two anesthesiologists who were frustrated with the current status quo of treatment outcomes for cancer. Dr. Arun Anand and Dr. Andrew Roberts teamed up to challenge the conventional view that cancer originates from random mutations and to devote more attention to an often overlooked commonality: Cancer cells use different metabolic pathways for energy production — and this can be targeted. Based on this principle, Tieös is developing small molecule drugs that starve cancer cells of energy and prevent cancer from multiplying using cutting-edge computational biology and artificial intelligence algorithms.

Umay Care

Ali Habib, founder and CEO of Umay Care, was first inspired to start his company when he was diagnosed with Meibomian Gland Dysfunction, which is the leading cause of dry eye in North America and affects more than 300 million people globally. Before 2007, age was the leading cause of dry eye, but that changed with the rise of smartphones. Today, most people spend almost 11 hours in front of a screen every day — not only on their phone, but on computers at work and TVs at home. This trend has led to ‘digital eye strain’ which leads to dry eye, makes it harder for people to sleep and can lead to stress and headaches. That’s why Ali created Umay Rest®, a digital device that uses thermal therapy and medication to help digital device users reset the effects of screen time and relieve stress before bedtime.

Health Gauge

Hypertension, and related cardiac diseases, are known as the silent killers — but Health Gauge aims to change that. With their personal care monitoring platform, Health Gauge is creating a better way to monitor, understand and manage hypertension — a leading case of lower life expectancy and mortality. Their mission is to help people live long, healthy and high-quality lives through better health monitoring and management.

Bellesoma

Bellesoma Co-founder Adam Cohen first learned about the tremendous trade-offs in breast lift surgery when his wife made the decision to undergo the procedure after giving birth to their two children. After consulting with several top plastic surgeons, they quickly learned that the procedure would leave highly visible scarring and would produce limited lift and temporary results, among the many other complications. This experience led Adam to Dr. Gary Horndeski. With his background in mathematics and engineering, Dr. Horndeski had developed an innovative bioengineering approach to breast lift, reduction and implant removal surgeries. Together, they founded Bellesoma to commercialize Dr. Horndeski’s technology to establish a new gold standard of care for these kinds of surgeries.